Epidemiology and Prevention Homoarginine, Cardiovascular Risk, and Mortality
暂无分享,去创建一个
W. März | C. Wanner | M. Kleber | S. Pilz | B. Winkelmann | E. Ritz | B. Böhm | C. Drechsler | A. Meinitzer | V. Krane | J. Fischer
[1] T. Laitinen,et al. Serum L-homoarginine concentration is elevated during normal pregnancy and is related to flow-mediated vasodilatation. , 2008, Circulation journal : official journal of the Japanese Circulation Society.
[2] C. Wanner,et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. , 2008, Kidney international.
[3] J. Bauersachs,et al. Endothelial dysfunction in heart failure. , 2008, Pharmacological reports : PR.
[4] J. Ribalta,et al. Reference values for plasma concentrations of asymmetrical dimethylarginine (ADMA) and other arginine metabolites in men after validation of a chromatographic method. , 2007, Clinica chimica acta; international journal of clinical chemistry.
[5] Simon Capewell,et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. , 2007, The New England journal of medicine.
[6] W. März,et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). , 2007, Clinical chemistry.
[7] Zhihong Yang,et al. Endothelial arginase: A new target in atherosclerosis , 2006, Current hypertension reports.
[8] J. Chin-Dusting,et al. AMINO ACIDS, ARGINASE AND NITRIC OXIDE IN VASCULAR HEALTH , 2006, Clinical and experimental pharmacology & physiology.
[9] H Tunstall-Pedoe,et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. , 2005, JAMA.
[10] Peter Libby,et al. The forgotten majority: unfinished business in cardiovascular risk reduction. , 2005, Journal of the American College of Cardiology.
[11] W. März,et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.
[12] Stanley L Hazen,et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. , 2005, JAMA.
[13] W. März,et al. Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline Characteristics , 2004, Kidney and Blood Pressure Research.
[14] G. Eknoyan,et al. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification , 2003, Annals of Internal Medicine.
[15] R. Nijveldt,et al. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. , 2002, Analytical biochemistry.
[16] W. März,et al. Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. , 2001, Pharmacogenomics.
[17] I. Lundquist,et al. Arginine-induced insulin release is decreased and glucagon increased in parallel with islet NO production. , 1998, American journal of physiology. Endocrinology and metabolism.
[18] P. Ponikowski,et al. Wasting as independent risk factor for mortality in chronic heart failure , 1997, The Lancet.
[19] A. Hrabák,et al. Comparison of substrate and inhibitor specificity of arginase and nitric oxide (NO) synthase for arginine analogues and related compounds in murine and rat macrophages. , 1994, Biochemical and biophysical research communications.
[20] P. Vallance,et al. The effect of malnutrition on cardiovascular mortality in dialysis patients: is L-arginine the answer? , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[21] Y. Yoshimura,et al. Sensitivity of intestinal alkaline phosphatase to L-homoarginine and its regulation by subunit-subunit interaction. , 1994, Japanese journal of pharmacology.
[22] P. Sanders,et al. Role of nitric oxide synthesis in salt-sensitive hypertension in Dahl/Rapp rats. , 1993, Hypertension.
[23] H. Erbersdobler,et al. Homoarginine labeling is suitable for determination of protein absorption in miniature pigs. , 1991, The Journal of nutrition.
[24] S. Moncada,et al. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[25] Richard Graham Knowles,et al. Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[26] W. Malaisse,et al. Stimulus-secretion coupling of arginine-induced insulin release. Uptake of metabolized and nonmetabolized cationic amino acids by pancreatic islets. , 1989, Endocrinology.
[27] W. Fishman,et al. L-Homoarginine. An organ-specific, uncompetitive inhibitor of human liver and bone alkaline phosphohydrolases. , 1972, The Journal of biological chemistry.
[28] R. Johnson,et al. Homoarginine synthesis by rat kidney. , 1969, Archives of biochemistry and biophysics.
[29] I. Wells,et al. Homocitrulline and Homoarginine Synthesis from Lysine , 1964, Science.